🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our Kv3.1 structures are out today in Nature Communications nature.com/articles/s4146… with comment from Martin Gunthorpe Autifony Therapeutics nature.com/articles/s4146… Centre for Medicines Discovery Thermo Fisher, @DelemotteLab & Manuel Covarrubias

It was nice session. Thanks Katharina for inviting me!

Structural basis for inhibition of the lysosomal two-pore channel TPC2 by a small molecule antagonist Congrats Gamma, Katharina L. Duerr, and colleagues from Centre for Medicines Discovery and elsewhere! cell.com/structure/full…

Great collaboration with the teams of Christian Grimm Lysolabmunich, Marco Keller and Franz Bracher from Universität München, as well as Gamma Chi and colleagues from Centre for Medicines Discovery, now published in @Structure Journal, revealing the MoA of TPC2 antagonist SG-094: cell.com/structure/full…

A wonderful collaboration of the Peijun Zhang Lab, Frank von Delft, Katharina L. Duerr, Loic Carrique, Huanyu Z. Li, STRUBIOxford, Pharmacology Oxford, Diamond Light Source, eBIC Beamline, and Centre for Medicines Discovery

Our Director of Protein Biochemistry & Structural Biology Katharina L. Duerr will be presenting at Gordon Research Conferences’ ‘New Insights into Structure, Function, and Regulation of Critical Membrane Transport Proteins in Health and Disease’ conference. grc.org/membrane-trans…

Descending to inhibit: Antagonist-induced downward shift of VSD II in TPC2 dlvr.it/TBwhhH

Excited to attend the EFMC conference in Rome next week and contribute to the session: “Impact of cryo-EM in Drug Discovery”

📣 Session 20 – The next speaker is Dr Katharina DÜRR from OMass Therapeutics who will talk about “Cryo-EM enables Structure-Based Drug Discovery for Membrane Protein Targets”. Keep following us! 🔬💡 #EFMCISMC24 #MedChem